| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/25/2010 | US20100048518 Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent |
| 02/25/2010 | US20100047364 Nutrient System for Individualized Responsive Dosing Regimens |
| 02/25/2010 | US20100047289 Universal tumor cell vaccine for anti cancer therapeutic and prophylactic utilization |
| 02/25/2010 | US20100047223 Pharmanutrient Composition(s) and System(s) for Individualized, Responsive Dosing Regimens |
| 02/25/2010 | US20100047218 Reversible immortalization |
| 02/25/2010 | US20100047209 Probiotic composition suitable for animals |
| 02/25/2010 | US20100047206 Powdery composition for nasal administration |
| 02/25/2010 | CA2735050A1 Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof |
| 02/25/2010 | CA2734972A1 An extended release pharmaceutical composition of entacapone or salts thereof |
| 02/25/2010 | CA2734734A1 Siderophore-mediated iron uptake in bacterial infection |
| 02/25/2010 | CA2734655A1 Combinations comprising bicyclic s1p lyase inhibitors |
| 02/25/2010 | CA2734585A1 Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| 02/24/2010 | EP2157101A1 HSP peptides and analogs for modulation of immune responses via antigen presenting cells |
| 02/24/2010 | EP2157097A1 Specific binding agents of human angiopoietin-2 |
| 02/24/2010 | EP2157092A1 Remedy for diabetes |
| 02/24/2010 | EP2156863A2 Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline reuptake inhibitors |
| 02/24/2010 | EP2156848A1 Low-molecule drug-containing nanoparticle having sustained release negatively charged group |
| 02/24/2010 | EP2156847A1 New combination of active ingredients containing an alpha1-antagonist and a PDE 4 inhibitor. |
| 02/24/2010 | EP2156846A1 Prophylactic or therapeutic agent for diarrhea |
| 02/24/2010 | EP2156833A1 Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient |
| 02/24/2010 | EP2156831A1 Augmented Cognitive Training |
| 02/24/2010 | EP2155227A1 New treatment for chemical substance addiction |
| 02/24/2010 | EP2155214A1 Method for pain control |
| 02/24/2010 | EP2155146A1 Methods and compositions for treating skin conditions |
| 02/24/2010 | EP1869185B1 Conjugate comprising p21 protein for the treatment of cancer |
| 02/24/2010 | EP1689381B1 Pharmaceutical composition comprising i.a. vitamin c, magnesium, green tea extract for retarding cardiovascular diseases (smc proliferation) |
| 02/24/2010 | EP1615615B1 Tamper-resistant products for opioid delivery |
| 02/24/2010 | EP1605976B1 PHENYLCARBOXYL ACID AMIDES AND IK r CHANNEL INHIBITORS COMBINATION AND THE USE THEREOF FOR TREATING ATRIAL ARRHYTHMIA |
| 02/24/2010 | EP1553962B1 Combination chemotherapy with chlorotoxin |
| 02/24/2010 | EP1294422B1 Medical System for Reducing Vascular Occlusions |
| 02/24/2010 | EP1033979B2 Combination of cyp2a6 enzyme inhibitors and nicotine and their therapeutic use |
| 02/24/2010 | EP0837696B1 Improved delivery of diagnostic and therapeutic agents to a target site |
| 02/24/2010 | CN101654673A Rna interference mediating small rna molecules |
| 02/24/2010 | CN101654672A Rna interference mediating small rna molecules |
| 02/24/2010 | CN101654479A Mammalian receptor proteins, agents, and methods relating thereto |
| 02/24/2010 | CN101653608A Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and histone deacetylase inhibitor and application thereof |
| 02/24/2010 | CN101653607A Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and mitogen extracellular kinase inhibitor and application thereof |
| 02/24/2010 | CN101653606A Pharmaceutical composition containing protein kinase B inhibitor and epidermal growth factor recipient tyrosine kinase inhibitor and application thereof |
| 02/24/2010 | CN101653605A Detoxification treatment, detoxification treatment set and dosing regimen |
| 02/24/2010 | CN101653604A Anti-ngf antibodies for the treatment of various disorders |
| 02/24/2010 | CN101653603A Peptides and antibodies binding to anionic phospholipids and aminophospholipids and their use in treating disease |
| 02/24/2010 | CN101653354A Noninvasive measurements of chemical substances |
| 02/24/2010 | CN100591355C Compositions for treating hyperproliferative conditions and its pharmaceutical uses |
| 02/24/2010 | CN100591331C Combination chemotherapy compositions |
| 02/24/2010 | CN100591320C Stable surfactant compositions for suspending components |
| 02/23/2010 | US7668659 Diagnosis and classification of multiple myeloma |
| 02/23/2010 | US7667013 Gene encoding a guanine nucleotide exchange factor and the gene product thereof |
| 02/23/2010 | US7667008 Heparin binding protein for use in controlling angiogenesis and as wound healing agent |
| 02/23/2010 | US7667002 Peptides and proteins for early liver development and antibodies thereto |
| 02/23/2010 | US7666914 Topical preparation and method for transdermal delivery and localization of therapeutic agents |
| 02/23/2010 | US7666910 Locating an artery which carries major blood supply to the tumor; intra-arterially injecting into the located artery a predetermined quantity of a polyunsaturated fatty acid solution and anti-antiogenic substances |
| 02/23/2010 | US7666876 Buprenorphine formulations for intranasal delivery |
| 02/23/2010 | US7666858 Pharmaceutical composition for treatment of phimosis using topical corticosteroid |
| 02/23/2010 | US7666849 Ribosome structure and protein synthesis inhibitors |
| 02/23/2010 | US7666843 Methods and compositions for treatment of neurological disorder |
| 02/23/2010 | US7666839 Methods of treatment using specific binding agents of human angiopoietin-2 |
| 02/23/2010 | US7666832 Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent |
| 02/23/2010 | US7666831 Administering peptibodies, i.e., peptides fused to other molecules such as an Fc domain of an antibody, where the peptide moiety specifically binds to Ang-2 ( angiopoietin-2); antiinflammatory agent; antirheumatic agent |
| 02/23/2010 | US7666829 Compositions for elastogenesis and connective tissue treatment |
| 02/23/2010 | US7666639 Plant deoxyribonucleoside kinase enzymes and their use |
| 02/23/2010 | US7666619 Compounds and methods for regulating bacterial growth and pathogenesis |
| 02/23/2010 | US7666453 Mineral oil, zinc oxide, gum karaya powder, tea tree oil, aloe vera and a fungicide amphotericin B, butoconazole, clotrimazole, fluconazole, miconazole, ketoconazole, flucytosine, terbinafine, itraconazole, and terconazole; diaper rash; psoriasis, eczema, ichthyosis, pruritus, dryness, dermatitis |
| 02/23/2010 | US7666447 Synergistically treating joint ailments, premenstrual tension, Syndrome X, cardiovascular disease, bone disorders; antidiabetic agents; peroxisome peroxidation activation receptor agonists |
| 02/23/2010 | US7666425 Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen or bind to and are internalized with prostate specific membrane antigen |
| 02/23/2010 | US7666422 Methods for the treatment of cancer using anti-CD40 antibodies |
| 02/23/2010 | US7666411 Administering to the subject an effective amount of a substance that binds to IL-13, wherein the substance that binds to IL-13 is an antibody and inhibits IL-13 activation of IL-13R alpha |
| 02/23/2010 | US7666401 Compositions comprising a ligand of Chemerin R |
| 02/23/2010 | CA2462289C Heteroaryl substituted tetrazole modulators of metabotropic glutamate receptor-5 |
| 02/23/2010 | CA2448596C Topical treatments using alkanolamines |
| 02/23/2010 | CA2378880C Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 02/23/2010 | CA2374102C Compositions containing creatine in suspension |
| 02/23/2010 | CA2297115C Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 02/23/2010 | CA2257852C Transgenic non-human mammals with progressive neurologic disease |
| 02/23/2010 | CA2232288C Treating niddm with rxr agonists |
| 02/18/2010 | WO2010018846A1 Drug containing antibody composition specifically binding to ganglioside gm2 |
| 02/18/2010 | WO2010018800A1 Acetyl pyrrolidinyl indole derivative |
| 02/18/2010 | WO2010018764A1 Anti-angiogenic agent, and screening method and screening kit for same |
| 02/18/2010 | WO2010018549A2 Therapeutic compositions containing macitentan |
| 02/18/2010 | WO2010017632A1 Methods for stimulating chondrogenesis utilizing a potassium channel inhibitor |
| 02/18/2010 | WO2009083521A3 Antibacterial compositions comprising an antiseptic in combination with an antibiotic |
| 02/18/2010 | WO2009080432A3 Composition for treatment of tuberculosis |
| 02/18/2010 | WO2008132712A3 Combination pharmaceutical compositions |
| 02/18/2010 | US20100041671 Methods for treating glaucoma |
| 02/18/2010 | US20100041624 Buprenorphine formulations for intranasal delivery |
| 02/18/2010 | US20100041072 Process for identifying a ligand that binds to the nep binding site for the smr1 pentapeptide |
| 02/18/2010 | US20100040691 Pharmaceutical compositions comprising methotrexate |
| 02/18/2010 | US20100040668 Biomimetic Hydroxyapatite Composite Materials and Methods for the Preparation Thereof |
| 02/18/2010 | US20100040645 In vivo ctl elicitation by heat shock protein fusion proteins maps to a discrete domain and is cd4+ t cell-independent |
| 02/18/2010 | US20100040589 Novel Compositions and Uses Thereof |
| 02/18/2010 | US20100040587 Cells for therapy of the heart, method of obtaining a cell preparation, and cell preparation |
| 02/18/2010 | US20100040586 Treatment of Injuries to the Central Nervous System |
| 02/18/2010 | US20100040575 Use of inhibitors of glutaminyl cyclase and glutamate cyclase for treatment and prevention of neurodegenerative diseases |
| 02/18/2010 | US20100040539 Vector System |
| 02/18/2010 | DE102008039417A1 Mittel zum Nachweis und zur Behandlung von Prostatazellen Means for the detection and treatment of prostate cells |
| 02/18/2010 | CA2733646A1 Acetyl pyrrolidinyl indole derivative |
| 02/18/2010 | CA2731370A1 Therapeutic compositions containing macitentan |
| 02/17/2010 | EP2154139A1 Bicyclic heterocyclic compound |
| 02/17/2010 | EP2153849A2 Contraception process and administration form for the same |
| 02/17/2010 | EP2153846A1 Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immonostimulatory molecule |
| 02/17/2010 | EP2153840A1 Therapeutic agent and detection reagent for arteriosclerotic disease which targets for thallusin |